Soehnlein, Oliver http://orcid.org/0000-0002-7854-0694
Libby, Peter http://orcid.org/0000-0002-1502-502X
Article History
Accepted: 29 March 2021
First Online: 11 May 2021
Competing interests
: O.S. holds two patents on targeting histones in inflammation and one on disrupting CCL5-HNP1 heteromers, and also receives funding from Novo Nordisk to study chronopharmacological treatment strategies in cardiovascular disease. P.L. is a member of the scientific advisory board for Amgen, Corvidia Therapeutics, DalCor Pharmaceuticals, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis and XBiotech, Inc. P.L.’s laboratory has received research funding in the past 2 years from Novartis. P.L. is on the Board of Directors of XBiotech, Inc. P.L. has a financial interest in Xbiotech, a company developing therapeutic human antibodies. P.L.’s interests were reviewed and are managed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict of interest policies.
Free to read: This content has been made available to all.